P53-dependent Metabolic and Epigenetic Reprogramming in Carcinogenesis

Project description

A guardian angel turned devilish could reveal therapeutic targets for many cancers

Cancer is diverse and complex but many cancers show certain similarities. Mutations in the TP53 gene coding tumour protein 53 (p53) are most commonly associated with human cancers. As the 'guardian of the genome', p53 regulates cell division and acts as a tumour suppressor, stopping cells with mutated or damaged DNA from dividing. In addition, TP53 mutation alters cell metabolism, which in turn, can affect modifications to DNA that control gene expression (epigenetics), resulting in abnormal gene expression that further promotes cancer development. MetEpiC is investigating this cycle of interactions for a clearer understanding of pathways with implications for therapeutically targeting several types of cancers.

Fields of science

• natural sciences › biological sciences › cell biology › cell metabolism
• natural sciences › biological sciences › genetics › mutation
• medical and health sciences › clinical medicine › oncology
• natural sciences › biological sciences › genetics › epigenetics

Programme(s)

• H2020-EU.1.3. - EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions Main Programme
• H2020-EU.1.3.2. - Nurturing excellence by means of cross-border and cross-sector mobility

Topic(s)

• MSCA-IF-2018 - Individual Fellowships

Call for proposal

H2020-MSCA-IF-2018

See other projects for this call

Funding Scheme

MSCA-IF-EF-ST - Standard EF

Coordinator

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE

Net EU contribution

€ 196 707,84

Address

Rue De Tolbiac 101
75654 Paris
France

Region

Ile-de-France › Ile-de-France › Paris

Activity type

Research Organisations

Links

Non-EU contribution

€ 0,00